Heterogeneity of clonal development in chronic myeloproliferative disorders

Am J Hematol. 1999 Feb;60(2):158-60. doi: 10.1002/(sici)1096-8652(199902)60:2<158::aid-ajh14>3.0.co;2-9.

Abstract

Recent reports have suggested a previously unexpected variability in the expression of the dominant neoplastic clone in myeloproliferative disorders (MPD). We evaluated 49 female patients with MPD and informative at the X-linked androgen receptor (AR) locus to establish the X chromosome inactivation pattern of hemopoietic cells. Whereas in chronic myelogenous leukemia (CML) the granulocytes (PMN) were uniformly of monoclonal origin, a striking heterogeneity of clonal development was found in PMN from patients with other MPD, with up to 50% of them expressing a polyclonal pattern of X inactivation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • B-Lymphocytes / pathology
  • Clone Cells / pathology
  • Dosage Compensation, Genetic*
  • Female
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Middle Aged
  • Myeloproliferative Disorders / genetics*
  • Myeloproliferative Disorders / pathology*
  • Neutrophils / pathology
  • Polymerase Chain Reaction
  • Receptors, Androgen / genetics*
  • T-Lymphocytes / pathology

Substances

  • Receptors, Androgen